02/05/2012. Fleming researchers have revealed a major role for Autotaxin (ATX, ENPP2) and its bioactive lipid product lysophosphatidic acid (LPA) in the pathogenesis of rheumatoid arthritis. Their work establishes the ATX/LPA axis as a novel player in chronic inflammation and as a promising therapeutic target. [Pubmed]. See related research highlight.

30/01/2012. Using the EAE mouse model of Multiple Sclerosis (MS), Fleming researchers have uncovered the cellular basis of a pathologically significant role for TNFR2, the receptor of the proinflammatory cytokine TNF. In contrast to current concepts, the researchers have shown that TNFR2 on non-hematopoietic cells modulates regulatory T-cell function, providing novel insights into the mechanisms that drive MS pathology, and supporting future agonistic targeting of TNFR2 as a rational approach for the management of MS. This article is featured on the cover of the February issue of EJI. [Pubmed]

29/12/2011. Fleming Researchers (Kontoyiannis Group) revealed the importance of the mRNA regulator HuR, in inflammation supporting tumor development. Using transgenic systems for the deletion or overexpression of HuR in inflammatory cells, they unraveled unprecedented effects in mRNA regulation and demonstrated that enhancing HuR activity may be of clinical benefit in the battle against pathologic inflammation and colitis associated cancer. See Article and related Commentary.

Introducing Biomedcode Hellas SA.
A spin off company of BSRC "Alexander Fleming" providing pre-clinical drug evaluation services to pharmaceutical companies using disease animal models.

The Center has established six core facilities to offer internal and external users direct access to its research infrastructures. The animal house facility, protein chemistry lab, expression profiling facility, transgenic facility, flow cytometry facility, innovation and enterprise unit, genotyping facility and BioIT unit are actively involved in collaborations with both academic and industrial partners.

The BSRC Fleming participates in a number of International programs. Such collaborations are of significant importance for the exchange and dissemination of knowledge and expertise as well as bring together major groups around the world for the study and therapy of human disease.